Durvalumab

• Partly comes backHeart muscle and circulation: Myocarditis from immunotherapy is rare but serious: survivors can recover heart function, yet the risk of dying stays roughly doubled for a year afterwards and is still raised at five years. one-year mortality 38.9% after checkpoint-associated myocarditis against 20.8% in matched myocarditis of other causes, and 47.8% against 34.3% at five years (matched cohorts in a federated health records network, 226 patients with checkpoint-associated myocarditis). Outcomes of pericarditis and myocarditis on checkpoint inhibitors, Journal of the American Heart Association 2026
• Usually comes backLungs: Immunotherapy pneumonitis usually clears with steroids and seldom becomes permanent, but it comes back in roughly one in twelve people, and more often in those who already had scarred lungs. recurrence 8.3% with no prior lung disease, 9.1% with chronic obstructive pulmonary disease and 16.4% with pre-existing interstitial lung disease (matched cohorts of 3,147 patients each, drawn from more than 184,000 checkpoint inhibitor recipients in a federated health records network). Checkpoint inhibitor pneumonitis in lung cancer with chronic lung disease, Respirology 2026
• Partly comes backNerves in the hands and feet: Nerve problems caused by immunotherapy are among the toxicities most likely to stay after treatment ends, and about three quarters of them became long-term. 11 of 15 neurotoxicities became chronic (387 patients given adjuvant anti-PD-1 for stage III to IV melanoma at eight academic centres). Chronic immune-related adverse events after adjuvant anti-PD-1, JAMA Oncology 2021
• Does not usually come backHormone glands: If immunotherapy inflames the pituitary, the gland's control of the adrenal glands almost never comes back, so steroid replacement is usually for life, though the thyroid and sex-hormone axes recover in some people. none of 22 recovered secondary adrenal insufficiency; the thyroid axis recovered in 33% and the gonadal axis in 67% (22 patients with checkpoint-induced hypophysitis at a tertiary endocrine and immunotherapy clinic). Checkpoint inhibitor hypophysitis in a tertiary centre, Clinical Endocrinology 2026
• Does not usually come backHormone glands: Thyroid inflammation from immunotherapy often burns the gland out, and when it does the thyroid does not restart, so levothyroxine is usually lifelong. only 2 of 103 regained their own thyroid function, while 64 reached normal levels on levothyroxine; in a separate cohort 53 of 124 progressed to permanent hypothyroidism (103 patients with checkpoint-associated thyroiditis at an academic centre, and 124 at Montefiore between 2016 and 2021). Levothyroxine dosing in checkpoint-associated hypothyroidism, Thyroid 2022
• Does not usually come backHormone glands: Adrenal insufficiency caused by immunotherapy generally does not reverse, and people are still taking replacement steroids years after the immunotherapy itself has finished. of 93 patients whose immune side effects were still present at last follow-up, 24 (25.8%) were on systemic steroids, 16 of them replacement for hypophysitis or adrenal insufficiency (318 patients given adjuvant anti-PD-1 for resected melanoma at six centres in the United States and Australia). Extended follow-up of chronic immune-related adverse events, JAMA Network Open 2023

Read for the class this product belongs to (immune checkpoint inhibitors) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.